Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 7/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18554372 | 0.88 | TGFBR1 (0.56) | TGFBR1PDGFRACCNE1CDK2CTSL | |
| SCHEMBL18554195 | 0.88 | TGFBR1 (0.52) | TGFBR1PDGFRACCNE1CDK2YTHDC1 | |
| SCHEMBL18554192 | 0.88 | TGFBR1 (0.50) | TGFBR1HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL18554302 | 0.85 | PDGFRA (0.43) | TGFBR1PDGFRACCNE1CDK2YTHDC1 | |
| SCHEMBL18554119 | 0.84 | PDGFRA (0.46) | TGFBR1PDGFRACCNE1CDK2YTHDC1 | |
| SCHEMBL18554294 | 0.84 | PDGFRA (0.48) | TGFBR1PDGFRACCNE1CDK2YTHDC1 | |
| SCHEMBL23007800 | 0.83 | CNR2 (0.44) | PDGFRACCNE1CDK2YTHDC1CTSL | |
| SCHEMBL29363336 | 0.83 | CNR2 (0.44) | PDGFRACCNE1CDK2YTHDC1CTSL | |
| SCHEMBL18583683 | 0.81 | TGFBR1 (0.57) | TGFBR1HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL18554193 | 0.81 | TGFBR1 (0.55) | TGFBR1HDAC1HDAC3HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180250303-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-06 | — | — | US | disclosed |
| EP-3341372-A1 | TGF BETA RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017035118-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2017035118-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180250303-A1 | TGF BETA RECEPTOR ANTAGONISTS | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885PDGFRA 51/4885CCNE1 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.